JP7483234B2 - Hivワクチン免疫原 - Google Patents

Hivワクチン免疫原 Download PDF

Info

Publication number
JP7483234B2
JP7483234B2 JP2021531557A JP2021531557A JP7483234B2 JP 7483234 B2 JP7483234 B2 JP 7483234B2 JP 2021531557 A JP2021531557 A JP 2021531557A JP 2021531557 A JP2021531557 A JP 2021531557A JP 7483234 B2 JP7483234 B2 JP 7483234B2
Authority
JP
Japan
Prior art keywords
polypeptide
subject
glycan
nucleic acid
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513438A5 (cg-RX-API-DMAC7.html
JP2022513438A (ja
Inventor
ヌーゼンツヴァイク,ミシェル
ビョルクマン,パメラ,ジェイ.
エスコラーノ,アメリア
グリスティック,ハリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2022513438A publication Critical patent/JP2022513438A/ja
Publication of JP2022513438A5 publication Critical patent/JP2022513438A5/ja
Priority to JP2024068841A priority Critical patent/JP2024099671A/ja
Application granted granted Critical
Publication of JP7483234B2 publication Critical patent/JP7483234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021531557A 2018-12-04 2019-11-27 Hivワクチン免疫原 Active JP7483234B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024068841A JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775192P 2018-12-04 2018-12-04
US62/775,192 2018-12-04
PCT/US2019/063619 WO2020117590A1 (en) 2018-12-04 2019-11-27 Hiv vaccine immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024068841A Division JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Publications (3)

Publication Number Publication Date
JP2022513438A JP2022513438A (ja) 2022-02-08
JP2022513438A5 JP2022513438A5 (cg-RX-API-DMAC7.html) 2022-11-18
JP7483234B2 true JP7483234B2 (ja) 2024-05-15

Family

ID=70974318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531557A Active JP7483234B2 (ja) 2018-12-04 2019-11-27 Hivワクチン免疫原
JP2024068841A Pending JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024068841A Pending JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Country Status (10)

Country Link
US (2) US12239698B2 (cg-RX-API-DMAC7.html)
EP (2) EP3891170B1 (cg-RX-API-DMAC7.html)
JP (2) JP7483234B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210124205A (cg-RX-API-DMAC7.html)
CN (2) CN113454100B (cg-RX-API-DMAC7.html)
AU (2) AU2019393745B2 (cg-RX-API-DMAC7.html)
CA (1) CA3120324A1 (cg-RX-API-DMAC7.html)
ES (1) ES2993834T3 (cg-RX-API-DMAC7.html)
PL (1) PL3891170T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020117590A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732898B (zh) * 2022-04-01 2023-05-09 中国人民解放军军事科学院军事医学研究院 一种CpG佐剂与抗原定点共价结合方法
US20260207733A1 (en) * 2022-12-15 2026-07-23 The Wistar Institute Of Anatomy And Biology Hiv immunogens and methods of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140212458A1 (en) 2012-11-05 2014-07-31 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
WO2015134982A1 (en) 2014-03-07 2015-09-11 Cornell University Materials and methods for producing cleaved, hiv-1 envelop glycoprotein trimers
WO2017165674A1 (en) 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
WO2018161049A1 (en) 2017-03-03 2018-09-07 Duke University Compositions and methods for inducing hiv-1 antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
IE922436A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU2002336417A1 (en) 2001-08-31 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Methods of generating human cd4+ th1 cells
US8673307B1 (en) * 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
HRP20200583T1 (hr) * 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protutijela koja neutraliziraju gp120 i njihova upotreba
WO2016196975A1 (en) * 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
WO2017055522A1 (en) * 2015-09-29 2017-04-06 Academisch Medisch Centrum Stabilized env proteins of hiv
WO2019169356A1 (en) * 2018-03-02 2019-09-06 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140212458A1 (en) 2012-11-05 2014-07-31 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
WO2015134982A1 (en) 2014-03-07 2015-09-11 Cornell University Materials and methods for producing cleaved, hiv-1 envelop glycoprotein trimers
WO2017165674A1 (en) 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
WO2018161049A1 (en) 2017-03-03 2018-09-07 Duke University Compositions and methods for inducing hiv-1 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Escolano A. et al.,Nature,2019年06月27日,Vol. 570,pp. 468-473, Extended Data
Steichen JM. et al.,Immunity,2016年,Vol. 45,pp. 483-496

Also Published As

Publication number Publication date
CN113454100B (zh) 2024-08-23
US20220031830A1 (en) 2022-02-03
EP4464380A3 (en) 2025-05-07
AU2019393745A1 (en) 2021-06-10
CA3120324A1 (en) 2020-06-11
WO2020117590A1 (en) 2020-06-11
EP3891170A4 (en) 2022-12-07
EP4464380A2 (en) 2024-11-20
EP3891170C0 (en) 2024-07-31
CN113454100A (zh) 2021-09-28
EP3891170A1 (en) 2021-10-13
US12239698B2 (en) 2025-03-04
JP2024099671A (ja) 2024-07-25
KR20210124205A (ko) 2021-10-14
JP2022513438A (ja) 2022-02-08
AU2025242201A1 (en) 2026-01-15
EP3891170B1 (en) 2024-07-31
ES2993834T3 (en) 2025-01-10
PL3891170T3 (pl) 2024-12-02
AU2019393745B2 (en) 2025-08-07
CN119241692A (zh) 2025-01-03
US20250144197A1 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
JP7536737B2 (ja) Hpv及びhpv関連疾患に対する新規のワクチン
US20250144197A1 (en) Hiv vaccine immunogens
KR20190090005A (ko) Cd127에 대해 지시된 항체 및 폴리펩타이드
JP2019126343A (ja) 生体外での効率的な定向増幅用のキメラ抗原受容体及びその適用
DK2668959T3 (en) Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
US9775895B2 (en) HIV therapeutics and methods of making and using same
CN110054698A (zh) 抗cd19抗体的新型cd19-car载体的构建及应用
CN108779168A (zh) Hiv结合剂
US20250057933A1 (en) Rhinovirus Vaccine
EP3800199B1 (en) H3.3 ctl peptides and uses thereof
HK40119361A (en) Hiv vaccine immunogens
HK40119313A (en) Hiv vaccine immunogens
HK40053334B (en) Hiv vaccine immunogens
HK40051015A (en) Hiv vaccine immunogens
HK40051015B (en) Hiv vaccine immunogens
HK40053334A (en) Hiv vaccine immunogens
WO2012040266A2 (en) Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
US20240033341A1 (en) Hiv vaccine immunogens
JP7086000B2 (ja) 体液性親和性の加速に関する方法及び組成物
US20240277829A1 (en) Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
CN114790248A (zh) MUC1-PDL1-IgG1 Fc肿瘤疫苗及其制备方法和应用
Melief et al. IgG-Mediated Anaphylaxis to a Synthetic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240422

R150 Certificate of patent or registration of utility model

Ref document number: 7483234

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150